Literature DB >> 28925892

Natural Active Compounds from Plant Food and Chinese Herbal Medicine for Nonalcoholic Fatty Liver Disease.

Qian Liu1,2, Lixin Zhu3, Chen Cheng1,4, Yi-Yang Hu1,4,5, Qin Feng1,4.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) has become more prevalent worldwide. It is often associated with some metabolic diseases, such as obesity, type 2 diabetes, and metabolic syndrome. With increasing focus on the treatment of fatty liver, much attention has been paid to numerous medicinal herbs and dietary substances to provide a new strategy for NAFLD treatment. The natural active compounds from the herbs or diet have been studied as promising treatments for NAFLD. This study aimed to summarize the use and mechanism of action of natural active compounds in the treatment of NAFLD in the recent 10 years. An updated search was conducted on the PubMed, Web of Science, and Google Scholar databases from 2006 (for studies on silibinin, resveratrol, curcumin, and berberine compounds since 2010). Fifty-nine active compounds for NAFLD treatment were presented in detail in textual form and tabular form according to their chemical classification. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Active compounds; Chinese herbal medicine; nonalcoholic fatty liver disease; obesity; plant food; type 2 diabetes

Mesh:

Substances:

Year:  2017        PMID: 28925892     DOI: 10.2174/1381612823666170918120643

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  8 in total

1.  Phenolic Compounds from Carissa spinarum Are Characterized by Their Antioxidant, Anti-Inflammatory and Hepatoprotective Activities.

Authors:  Ye Liu; Yongli Zhang; Felix Wambua Muema; Festus Kimutai; Guilin Chen; Mingquan Guo
Journal:  Antioxidants (Basel)       Date:  2021-04-23

2.  Identify Molecular Mechanisms of Jiangzhi Decoction on Nonalcoholic Fatty Liver Disease by Network Pharmacology Analysis and Experimental Validation.

Authors:  Lei Wang; Yin Zhi; Ying Ye; Miao Zhang; Xing Ma; Hongyun Tie; Xiaokun Ma; Ni Zheng; Wei Xia; Yanan Song
Journal:  Biomed Res Int       Date:  2020-12-12       Impact factor: 3.411

Review 3.  Therapeutic Potential of Natural Plants Against Non-Alcoholic Fatty Liver Disease: Targeting the Interplay Between Gut Microbiota and Bile Acids.

Authors:  QinMei Sun; Xin Xin; ZiMing An; YiYang Hu; Qin Feng
Journal:  Front Cell Infect Microbiol       Date:  2022-03-09       Impact factor: 5.293

4.  Exploring the Protective Effects and Mechanism of Huaji Jianpi Decoction against Nonalcoholic Fatty Liver Disease by Network Pharmacology and Experimental Validation.

Authors:  Hongkun Xue; Yu Wang; Hongwei Xiang; Qi Song; Guowei Zhang; Jianguo Wang; Shaoqin Ge
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-26       Impact factor: 2.650

5.  Gypenosides improves nonalcoholic fatty liver disease induced by high-fat diet induced through regulating LPS/TLR4 signaling pathway.

Authors:  Shuhua Shen; Kungen Wang; Yihui Zhi; Wei Shen; Liquan Huang
Journal:  Cell Cycle       Date:  2020-10-29       Impact factor: 4.534

6.  A Combination of Geniposide and Chlorogenic Acid Combination Ameliorates Nonalcoholic Steatohepatitis in Mice by Inhibiting Kupffer Cell Activation.

Authors:  Xin Xin; Yue Jin; Xin Wang; Beiyu Cai; Ziming An; Yi-Yang Hu; Qin Feng
Journal:  Biomed Res Int       Date:  2021-05-13       Impact factor: 3.411

7.  Hepatic Proteomic Changes and Sirt1/AMPK Signaling Activation by Oxymatrine Treatment in Rats With Non-alcoholic Steatosis.

Authors:  Hong Xu; Gao-Feng Chen; Yu-Shui Ma; Hong-Wei Zhang; Yang Zhou; Guang-Hui Liu; Dong-Ya Chen; Jian Ping; Yi-Hui Liu; Xin Mou; Da Fu
Journal:  Front Pharmacol       Date:  2020-03-10       Impact factor: 5.810

Review 8.  The Impacts of Herbal Medicines and Natural Products on Regulating the Hepatic Lipid Metabolism.

Authors:  Sha Li; Yu Xu; Wei Guo; Feiyu Chen; Cheng Zhang; Hor Yue Tan; Ning Wang; Yibin Feng
Journal:  Front Pharmacol       Date:  2020-03-24       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.